De Novo vs Nevus-Associated Melanomas: Differences in Associations With Prognostic Indicators and Survival

Journal of the National Cancer Institute

Volumn 108, Issue 10, 2016, Pages

  Cymerman, Rachel M ^a   Shao, Yongzhao ^a,b   Wang, Kun ^a   Zhang, Yilong ^a   Murzaku, Era C ^a   Penn, Lauren A ^a   Osman, Iman ^a,b   Polsky, David ^a,b  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGE; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CUTANEOUS MELANOMA; DE NOVO MELANOMA; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; INDEPENDENT VARIABLE; MAJOR CLINICAL STUDY; MALE; MITOSIS INDEX; NEVUS; NEVUS ASSOCIATED MELANOMA; ONCOGENESIS AND MALIGNANT TRANSFORMATION; OVERALL SURVIVAL; PATHOLOGICAL ANATOMY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEX DIFFERENCE; SHORT TERM SURVIVAL; TUMOR CLASSIFICATION; TUMOR DIFFERENTIATION; TUMOR ULCERATION; TUMOR VOLUME; ULCER; ADOLESCENT; ANALYSIS OF VARIANCE; CELL TRANSFORMATION; CHILD; COMPLICATION; EPIDEMIOLOGY; MELANOMA; MIDDLE AGED; MORTALITY; NEW YORK; PATHOLOGY; PIGMENTED NEVUS; PROGNOSIS; PROSPECTIVE STUDY; SKIN TUMOR; SKIN ULCER; SURVIVAL RATE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; CELL TRANSFORMATION, NEOPLASTIC; CHILD; FEMALE; HUMANS; MALE; MELANOMA; MIDDLE AGED; NEOPLASM STAGING; NEVUS, PIGMENTED; NEW YORK; PROGNOSIS; PROSPECTIVE STUDIES; SEX FACTORS; SKIN NEOPLASMS; SKIN ULCER; SURVIVAL RATE; YOUNG ADULT;

EID: 84994378069     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djw121     Document Type: Article

References (42)

1. Goldstein AM, Tucker MA. Dysplastic nevi and melanoma. Cancer Epidemiol Biomarkers Prev. 2013;22 (4):528-532.
2. Stolz W, Schmoeckel C, Landthaler M, et al. Association of early malignant melanoma with nevocytic nevi. Cancer. 1989;63 (3):550-555.
3. Black WC. Residual dysplastic and other nevi in superficial spreading melanoma. Clinical correlations and association with sun damage. Cancer. 1988; 62 (1):163-173.
4. Clark WH Jr, Elder DE, Guerry Dt, et al. A study of tumor progression: the precursor lesions of superficial spreading and nodular melanoma. Hum Pathol. 1984;15 (12):1147-1165.
5. Cook MG, Robertson I. Melanocytic dysplasia and melanoma. Histopathology. 1985;9 (6):647-658.
6. Harley S, Walsh N. A new look at nevus-associated melanomas. Am J Dermatopathol. 1996;18 (2):137-141.
7. Hastrup N, Osterlind A, Drzewiecki KT, et al. The presence of dysplastic nevus remnants in malignant melanomas. A population-based study of 551 malignant melanomas. Am J Dermatopathol. 1991;13 (4):378-385.
8. Massi D, Carli P, Franchi A, et al. Naevus-associated melanomas: cause or chance? Melanoma Res. 1999;9 (1):85-91.
9. Sagebiel RW. Melanocytic nevi in histologic association with primary cutaneous melanoma of superficial spreading and nodular types: effect of tumor thickness. J Invest Dermatol. 1993;100 (3):322S-325S.
10. Shain AH, Yeh I, Kovalyshyn I, et al. The Genetic Evolution of Melanoma from Precursor Lesions. N Engl J Med. 2015;373 (20):1926-1936.
11. Bastian BC. The molecular pathology of melanoma: an integrated taxonomy of melanocytic neoplasia. Annu Rev Pathol. 2014;9:239-271.
12. Tucker MA, Halpern A, Holly EA, et al. Clinically recognized dysplastic nevi. A central risk factor for cutaneous melanoma. JAMA. 1997;277 (18): 1439-1444.
13. Lazovich D, Vogel RI, Berwick M, et al. Indoor tanning and risk of melanoma: a case-control study in a highly exposed population. Cancer Epidemiol Biomarkers Prev. 2010;19 (6):1557-1568.
14. Tsao H, Bevona C, Goggins W, et al. The transformation rate of moles (melanocytic nevi) into cutaneous melanoma: a population-based estimate. Arch Dermatol. 2003;139 (3):282-288.
15. Kvaskoff M, Pandeya N, Green AC, et al. Site-specific determinants of cutaneous melanoma: a case-case comparison of patients with tumors arising on the head or trunk. Cancer Epidemiol Biomarkers Prev. 2013;22 (12): 2222-2231.
16. Whiteman DC, Pavan WJ, Bastian BC. The melanomas: a synthesis of epidemiological, clinical, histopathological, genetic, and biological aspects, supporting distinct subtypes, causal pathways, and cells of origin. Pigment Cell Melanoma Res. 2011;24 (5):879-897.
17. Whiteman DC, Watt P, Purdie DM, et al. Melanocytic nevi, solar keratoses, and divergent pathways to cutaneous melanoma. J Natl Cancer Inst. 2003; 95 (11):806-812.
18. Whiteman DC, Stickley M, Watt P, et al. Anatomic site, sun exposure, and risk of cutaneous melanoma. J Clin Oncol. 2006;24 (19):3172-3177.
19. Purdue MP, From L, Armstrong BK, et al. Etiologic and other factors predicting nevus-associated cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev. 2005;14 (8):2015-2022.
20. Friedman RJ, Rigel DS, Kopf AW, et al. Favorable prognosis for malignant melanomas associated with acquired melanocytic nevi. Arch Dermatol. 1983; 119 (6):455-462.
21. Lin WM, Luo S, Muzikansky A, et al. Outcome of patients with de novo versus nevus-associated melanoma. J Am Acad Dermatol. 2015;72 (1):54-58.
22. Weatherhead SC, Haniffa M, Lawrence CM. Melanomas arising from naevi and de novo melanomas-does origin matter? Br J Dermatol. 2007;156 (1): 72-76.
23. Garcia-Cruz A, Florez A, de la Torre-Fraga C, et al. Observational cross-sectional study comparing Breslow thickness of melanoma arising from naevi and melanoma de novo. Br J Dermatol. 2009;161 (3):700-702.
24. Wich LG, Hamilton HK, Shapiro RL, et al. Developing a multidisciplinary prospective melanoma biospecimen repository to advance translational research. Am J Transl Res. 2009;1 (1):35-43.
25. Thompson JF, Soong SJ, Balch CM, et al. Prognostic significance of mitotic rate in localized primary cutaneous melanoma: an analysis of patients in the multi-institutional American Joint Committee on Cancer melanoma staging database. J Clin Oncol. 2011;29 (16):2199-2205.
26. Garbe C, Buttner P, Bertz J, et al. Primary cutaneous melanoma. Prognostic classification of anatomic location. Cancer. 1995;75 (10):2492-2498.
27. Clark WH Jr, Elder DE, Guerry Dt, et al. Model predicting survival in stage I melanoma based on tumor progression. J Natl Cancer Inst. 1989;81 (24): 1893-1904.
28. Balch CM, Soong SJ, Gershenwald JE, et al. Prognostic factors analysis of 17, 600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J Clin Oncol. 2001; 19 (16):3622-3634.
29. Hemo Y, Gutman M, Klausner JM. Anatomic site of primary melanoma is associated with depth of invasion. Arch Surg. 1999;134 (2):148-150.
30. Kaddu S, Smolle J, Zenahlik P, et al. Melanoma with benign melanocytic naevus components: reappraisal of clinicopathological features and prognosis. Melanoma Res. 2002;12 (3):271-278.
31. Jones WM, Williams WJ, Roberts MM, et al. Malignant melanoma of the skin: prognostic value of clinical features and the role of treatment in 111 cases. Br J Cancer. 1968;22 (3):437-451.
32. MacKie RM. Malignant melanoma: clinical variants and prognostic indicators. Clin Exp Dermatol. 2000;25 (6):471-475.
33. Joosse A, van der Ploeg AP, Haydu LE, et al. Sex differences in melanoma survival are not related to mitotic rate of the primary tumor. Ann Surg Oncol. 2015;22 (5):1598-1603.
34. Joosse A, Collette S, Suciu S, et al. Superior outcome of women with stage I/II cutaneous melanoma: pooled analysis of four European Organisation for Research and Treatment of Cancer phase III trials. J Clin Oncol. 2012;30 (18): 2240-2247.
35. Joosse A, Collette S, Suciu S, et al. Sex is an independent prognostic indicator for survival and relapse/progression-free survival in metastasized stage III to IV melanoma: a pooled analysis of five European organisation for research and treatment of cancer randomized controlled trials. J Clin Oncol. 2013; 31 (18):2337-2346.
36. Joosse A, de Vries E, Eckel R, et al. Gender differences in melanoma survival: female patients have a decreased risk of metastasis. J Invest Dermatol. 2011; 131 (3):719-726.
37. Lasithiotakis K, Leiter U, Meier F, et al. Age and gender are significant independent predictors of survival in primary cutaneous melanoma. Cancer. 2008;112 (8):1795-1804.
38. Mervic L, Leiter U, Meier F, et al. Sex differences in survival of cutaneous melanoma are age dependent: an analysis of 7338 patients. Melanoma Res. 2011; 21 (3):244-252.
39. Sanlorenzo M, Ribero S, Osella-Abate S, et al. Prognostic differences across sexes in melanoma patients: what has changed from the past? Melanoma Res. 2014;24 (6):568-576.
40. de Vries E, Nijsten TE, Visser O, et al. Superior survival of females among 10, 538 Dutch melanoma patients is independent of Breslow thickness, histologic type and tumor site. Ann Oncol. 2008;19 (3):583-589.
41. Cook MB, McGlynn KA, Devesa SS, et al. Sex disparities in cancer mortality and survival. Cancer Epidemiol Biomarkers Prev. 2011;20 (8): 1629-1637.
42. Shen S, Wolfe R, McLean CA, et al. Characteristics and associations of highmitotic-rate melanoma. JAMA Dermatol. 2014;150 (10):1048-1055.